What's the Outlook for AstraZeneca Stock?
British pharmaceutical giant AstraZeneca (NYSE: AZN) has been in the news this year for its partnership with Oxford University on a COVID-19 vaccine that's one of the leaders in the race for regulatory authorization. This consistent growth stock is up 14% in 2020 and 26% from a year ago. What's ahead for the company, and can the stock continue a steady ascent that started nearly four years ago?
AstraZeneca delivered a stellar performance in the first half of 2020, with revenue increasing 14% in constant currency and core earnings per share growing 26% from the first half last year. The company won't commit to growth that hot in the second half of the year. Still, positive news of success for the company's newest drugs, its efforts to fight COVID-19, and its pipeline advancements should continue to be a tailwind for the company.
Image source: Getty Images
Source Fool.com
